Sanofi: 5-Star Dividend Stocks Poised to Outperform
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, French pharmaceutical giant Sanofi (NYS: SNY) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Sanofi and see what CAPS investors are saying about the stock right now.
Sanofi facts
Headquarters (founded) | Paris (1970) |
Market Cap | $114.4 billion |
Industry | Pharmaceuticals |
Trailing-12-Month Revenue | $46.9 billion |
Management | CEO Christopher Viehbacher (since 2008) |
Return on Equity (average, past 3 years) | 7.3% |
Cash/Debt | $6 billion / $21 billion |
Dividend Yield | 4% |
Competitors | GlaxoSmithKline (NYS: GSK) |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 981 members who have rated Sanofi believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, flynthewest, succinctly summed up the Sanofi bull case for our community:
Attach "Europe based" to nearly any company in this fall of 2012, and expect a measurable price discount. Add to that [Sanofi's] history of drug development and management coupled with the change growing population of drug consumers (read, more baby boomers aging), and you have a winner.
If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, Sanofi may not be your top choice.
If that's the case, we've compiled a special free report for investors called "Secure Your Future With 9 Rock-Solid Dividend Stocks," which uncovers several other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Sanofi: 5-Star Dividend Stocks Poised to Outperform originally appeared on Fool.com.
Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
